R&D Trends: Allergic Rhinitis - Immunotherapy takes a rising share of the pipeline

Date: March 1, 2011
Pages: 46
Price:
US$ 3,800.00
Publisher: Datamonitor
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: RE42819233EEN
Leaflet:

Download PDF Leaflet

R&D Trends: Allergic Rhinitis - Immunotherapy takes a rising share of the pipeline
Introduction

The 2011 pipeline shows strong interest in immunotherapy, which makes up 42% of products in development. Advancements in clinical trials and key partnerships are increasing exposure of this class. In this largely stable market, areas of innovation exist with nasal antihistamine/corticosteroid combinations remaining highly anticipated, while a number of novel targeted therapies raise skepticism.

Features and benefits
  • Assessment of the allergic rhinitis pipeline, drawing out trends by class and the potential to address unmet needs
  • Analysis of clinical trial design, highlighting innovation and anticipated future changes, with a focus on recent developments in immunotherapy
  • Discussion of novel early stage approaches and the future of treatment in allergic rhinitis, with insight from key opinion leaders

Highlights

Datamonitor has identified 60 products in development for allergic rhinitis. The late-stage pipeline is heavily skewed towards immunotherapy, which makes up 12 of 13 Phase III products. Immunotherapy shows the greatest innovation, with considerable change to clinical trials, and increased focus on sublingual tablet franchises.

Discussions with key opinion leaders reveal a largely stable market for symptomatic treatment; however, areas of innovation exist, such as the development of combination products. Analysis of comparator therapies highlights areas of unmet need.

A number of novel targeted therapies are moving through the pipeline, and two CRTH2 antagonists have reached Phase II. Key opinion leaders express skepticism over their clinical viability, with efficacy expected to fall short of established treatment classes. However, they may find a place in the treatment of select groups of patients.

Your key questions answered
  • Which characteristics of symptomatic treatments can be improved upon, and what would it take to create a new gold standard?
  • What are the driving forces behind allergic rhinitis clinical trial design and how has it evolved?
  • To what extent will the growing investment in immunotherapy change the future of treatment?
  • Is there value in novel targeted therapies or will current treatments continue to dominate?
EXECUTIVE SUMMARY

Strategic scoping and focus
Datamonitor key findings
Related reports

OVERVIEW

Catalyst
Summary

CLINICAL PIPELINE OVERVIEW

Allergen immunotherapy dominates late-stage pipeline
Analysis by formulation demonstrates innovation in the pipeline
Late-stage discontinued development compounds
  Epinastine nasal formulation (Inspire Pharmaceuticals)
  Loratadine/montelukast (Merck)
  Sublingual immunotherapies (Greer)

TARGET PRODUCT PROFILE

Telfast/Allegra (fexofenadine; Sanofi-Aventis)
  Pivotal trial data for Telfast/Allegra
Nasonex (mometasone; Merck & Co.)
  Pivotal trial data for Nasonex
Target product profile versus current level of attainment

CLINICAL TRIAL DESIGN IN ALLERGIC RHINITIS

Trends in clinical trial endpoints
  Symptom scores
Allergy challenges tackle seasonal variations
Study populations
Comparator drugs
Drug development guidelines in allergen immunotherapy
Typical allergic rhinitis clinical trials
  Symptomatic treatment
  Allergen immunotherapy
Future developments in clinical trial design

INNOVATIVE EARLY-STAGE APPROACHES

Sublingual immunotherapy franchises
Antihistamine combinations
Novel targeted therapies

THE FUTURE OF TREATMENT IN ALLERGIC RHINITIS

Combination antihistamine/corticosteroid therapy
Sublingual shift in immunotherapy

BIBLIOGRAPHY

Journal papers
Websites

APPENDIX

Contributing experts
Conferences attended
Report methodology

Ask Your Question

R&D Trends: Allergic Rhinitis - Immunotherapy takes a rising share of the pipeline
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: